Cytox Announces Participation in INSIGHT Alzheimer’s Study

Cytox Announces Participation in INSIGHT Alzheimer’s Study

Cytox Ltd, an innovative developer of assays for risk assessment and prediction of dementia, has confirmed its participation in the pioneering French INSIGHT study of Alzheimer’s disease (AD). The Cytox proposal, ‘Single Nucleotide Polymorphism (SNP) Profiling as an Approach to Risk Stratification for Future Cognitive Decline in Elderly Subjective Memory Complainers’, has been reviewed and approved by the INSIGHT Scientific Committee.

INSIGHT is a study of Alzheimer’s disease and one of the first in the world to monitor healthy subjects at risk. Led by Professor Harald Hampel, AXA-UPMC Chair at Université Pierre et Marie Curie, Paris, France and Professor Bruno Dubois, Director of IM2A (Institute of Memory and Alzheimer’s Disease, located at La Pitié Salpêtrière University Hospital in Paris), and based at the ICM (Brain and Spine Institute, Paris), the study is a collaboration with Pfizer and Avid.

See the article in full at VentureBeat.com

Important information

This information is of a general nature and does not constitute an offer to provide services.

The opinions and conclusions given here are those of Seneca Partners and are subject to change without notice.

The value of investments and/or any income arising from them may fluctuate.

Past performance is not necessarily a guide to future performance.

Important notice

The products and services shown on this website place capital at risk. Investors may receive less in returns than they have invested. Investments may not allow for capital to be withdrawn on demand. If an investment provides tax relief then this relief is subject to change and is dependant on personal circumstances. Any reference to past performance or forecasted performance is not a reliable indicator of future performance.

Seneca Partners recommends that any investor seeks specialised financial and/or tax advice before investing. Seneca Partners does not provide advice and the information on this website, including but not limited to news, should not be construed as such.

Please confirm that you understand this warning and wish to proceed.